Patents Expiring in December 2044
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF EDEMA IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | |||
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | |||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-001 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB | ||||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-001 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED EXTRA-PANCREATIC NEUROENDOCRINE TUMORS | ||||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-001 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED RENAL CELL CARCINOMA | ||||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-001 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED RENAL CELL CARCINOMA | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
